Skip to main content

Advertisement

Table 2 Baseline characteristics (treated set; n = 7034)

From: Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Age (years), mean (SD) 63.1 (8.6)
≥ 75 years of age, n (%) 652 (9)
Male, n (%) 5026 (72)
Race, n (%)  
 White 5089 (72)
 Asian 1518 (22)
 Black/African American 357 (5)
 Other* 70 (1)
Ethnicity, n (%)  
 Hispanic or Latino 1268 (18)
Smoking history, n (%) Current/Ex-smoker 930 (13)/3216 (46)
Time since diagnosis, n (%)  
 ≤5 years 1265 (18)
 >5-10 years 1754 (25)
 >10 years 4015 (57)
Region, n (%)  
 Europe 2885 (41)
 North America/Australia/New Zealand 1408 (20)
 Latin America 1081 (15)
 Africa 313 (4)
 Asia 1347 (19)
  Northeast Asia 586 (8)
  South/South-East Asia 761 (11)
CV risk factors, any of the below, n (%) 6978 (99)
 History of MI 3275 (47)
 Single-vessel CAD 743 (11)
 Multi-vessel CAD 3285(47)
 CABG 1738(25)
 History of stroke 1631 (23)
 Peripheral occlusive arterial disease 1449 (21)
Glucose-lowering therapy at baseline, n (%)  
 None 128 (2)
 Monotherapy 2055 (29)
  Metformin (% of monotherapy) 745 (36)
  Insulin (% of monotherapy) 954 (46)
 Dual therapy 3188 (45)
  Metformin + sulfonylurea (% of dual therapy) 1383 (43)
  Metformin + insulin (% of dual therapy) 1420 (45)
Other therapies (n, %)  
  Acetylsalicylic acid 5990 (85)
  Statins 5387 (77)
  Fibrates 630 (9)
 Any antihypertensive therapy (n, %) 6641 (94)
  Blockers of the renin-angiotensin system 5651 (80)
  Beta-blockers 4537 (64)
  Calcium channel blockers 2114 (30)
  1. *American Indian/Native Alaskan/Native Hawaiian/Pacific Islander/missing.
  2. Results (based on a pre-final version of the database of this ongoing trial) may change slightly once trial is completed.